JPRN-UMIN000049937已完成Unknown
Clinical Study on Efficacy of Pemafibrate in NAFLD (Non-Alcoholic Fatty Liver Disease) Patients with Dyslipidemia - SPND study
ippon Medical School, gastroenterology, Hiroki Ono0 个研究点目标入组 91 人开始时间: 2023年1月10日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 91
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The main exclusion criteria were as follows: (1) age <20\x{2009}years; (2) new administration of vitamin E, pioglitazone, SGLT2-Is, and GLP-1 RA known to be potentially effective for NAFLD and other antilipidemic agents within 12\x{2009}weeks prior to pemafibrate treatment; (3) decompensated cirrhosis; and (4) pregnancy or lactation.
研究者
相似试验
尚未招募
不适用
Clinical benefit of pemafibrate in patients with primary biliary cholangitis (PBC) with dyslipidemiaprimary biliary cholangitisJPRN-UMIN000039350Shinshu University Faculty of Medicine, Department of Gastroenterology60
已完成
4 期
PALT02JPRN-jRCT2031200177Ishibashi Shun20
招募中
3 期
Dalfampridine in improving spasticity in patients with severe brain traumaSevere traumatic brain injury.Diffuse traumatic brain injuryS06.2IRCT20221108056446N2Esfahan University of Medical Sciences80
已完成
不适用
Prospective randomized trial on Pemafibrate versus omega-3-acid ethyl in patients with untreated hypertriglyceridemiaHypertriglyceridemiaJPRN-UMIN000037026Sekino Hospital40
已完成
不适用
Prospective randomized trial on Pemafibrate versus omega-3-acid ethyl in patients with treated hypertriglyceridemiaHypertriglyceridemiaJPRN-UMIN000037110Sekino Hospital40